Activated immune cells after liver tumor removal for HCC
Part of Cancer, Digestive system clinical trials.
This Phase 2 study tests an immune-cell treatment (activated T lymphocytes) given after your liver cancer tumor has been fully removed. It aims to improve safety and reduce the chance of the cancer coming back in people with early-stage hepatocellular carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years or older and able to understand and sign consent.
- You have liver cancer (HCC) in stage I, II, or IIIa, confirmed by biopsy or imaging, and your tumor has been completely removed with curative treatment within about 12 weeks.
- Your liver is functioning well enough for Child-Pugh class A, and you must be able to do daily activities with ECOG score 1 or less.
- Your blood, kidney, and liver test numbers must meet limits (for example: ANC at least 1,500/µL, hemoglobin at least 9.0 g/dL).
- You must be able to have CT or MRI scans around the study times.
- If you can become pregnant (or partner with someone who can): you must use acceptable birth control during the study and for at least 24 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs before a liver transplant can help people with advanced liver cancer (beyond standard size limits) receive a transplant successfully. The treatment aims to shrink the tumor and improve outcomes.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
This Phase 2 trial studies durvalumab and tremelimumab (immunotherapy medicines) in people with resectable early or intermediate-stage liver cancer (HCC). It aims to see how well these medicines work before/around the time of surgery, and whether they can improve outcomes.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
This trial is testing a new treatment made from your own immune cells (called CT011 CAR-T cells) to see if it can lower the risk of liver cancer coming back after surgery. It is designed for people with advanced liver cancer that has spread into nearby blood vessels.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.